BriaCell Therapeutics Corp.

5.53-0.1900-3.32%Vol 1.39M1Y Perf -22.71%
Jun 14th, 2021 16:00 DELAYED
BID5.53 ASK5.62
Open5.79 Previous Close5.72
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap41.68M 
Earnings Rating
Price Range Ratio 52W %
43.94 
Earnings Date
5th Jul 2021

Today's Price Range

5.355.79

52W Range

2.819.00

5 Year PE Ratio Range

-3.50-3.00

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
7.38%
1 Month
75.00%
3 Months
37.91%
6 Months
27.86%
1 Year
-22.71%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCTX5.53-0.1900-3.32
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.58-
Q02 2020--1.99-
Q03 2019--0.01-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Jul 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.39M
Shares Outstanding7.54M
Trades Count6.04K
Dollar Volume3.50M
Avg. Volume2.57M
Avg. Weekly Volume3.15M
Avg. Monthly Volume9.29M
Avg. Quarterly Volume3.73M

BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock closed at 5.53 per share at the end of the most recent trading day (a -3.32% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 41.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. BriaCell Therapeutics Corp. CEO is William Williams.

The one-year performance of BriaCell Therapeutics Corp. stock is -22.71%, while year-to-date (YTD) performance is 32.61%. BCTX stock has a five-year performance of %. Its 52-week range is between 2.81 and 9, which gives BCTX stock a 52-week price range ratio of 43.94%

BriaCell Therapeutics Corp. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -370.57%, a ROC of -% and a ROE of 59.50%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BriaCell Therapeutics Corp., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BriaCell Therapeutics Corp.’s next earnings report date is 05th Jul 2021.

The consensus rating of Wall Street analysts for BriaCell Therapeutics Corp. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for BriaCell Therapeutics Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BriaCell Therapeutics Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BriaCell Therapeutics Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 58.76, ATR14 : 0.75, CCI20 : 77.25, Chaikin Money Flow : -0.59, MACD : 0.64, Money Flow Index : 89.39, ROC : 81.59, RSI : 64.67, STOCH (14,3) : 45.33, STOCH RSI : 0.20, UO : 39.97, Williams %R : -54.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BriaCell Therapeutics Corp. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

CEO: William Williams

Telephone: +1 604 921-1810

Address: 235 - 15th Street, Vancouver V7T 2X1, BC, CA

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

News

Stocktwits